IIT-GEORGE-I-PREDICT
Phase I/II
OPEN TO ACCRUAL
An Open-Label, Navigational Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy for Patients with Aggressive Malignancies and Poor Prognoses
MERCK-MK-5684-003
Phase III
OPEN TO ACCRUAL
A Phase 3 Randomized, Open-Label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Next-Generation Hormonal Agent (NHA) and Taxane-Based Chemotherapy
MERCK-MK-5684-004
Phase III
OPEN TO ACCRUAL
A Phase 3, Randomized, Open-Label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-Generation Hormonal Agent (NHA)
MERCK-MK-5684-01A
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2 Umbrella Substudy of MK-5684-U01 Master Protocol to Evaluate the Safety and Efficacy of MK-5684-Based Treatment Combinations or MK-5684 Alone in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
REGENERON-R15505-ONC-24144
Phase I/II
OPEN TO ACCRUAL
Phase 1/2 Study of REGN15505 (a PSMAx4-1BB Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN4336 (a PSMAxCD3 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma